| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | -0.031 | 0.5 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.047 | 0.6 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.096 | 0.6 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |